Literature DB >> 8871521

Different rifampicin inactivation mechanisms in Nocardia and related taxa.

Y Tanaka1, K Yazawa, E R Dabbs, K Nishikawa, H Komaki, Y Mikami, M Miyaji, N Morisaki, S Iwasaki.   

Abstract

Mycolic acid-containing bacteria inactivate rifampicin in a variety of ways such as glucosylation, ribosylation, phosphorylation and decolorization. These inactivations were found to be a species-specific phenomena in Nocardia and related taxa. Gordona, Tsukamurella and fast-growing Mycobacterium modified rifampicin by ribosylation of the 23-OH group of the antibiotic. Such ribosylation was not observed in Rhodococcus and Corynebacterium, but phosphorylation of the 21-OH group of rifampicin was observed in one strain of Rhodococcus. Nocardia modified the antibiotic by glucosylation (23-OH group) and phosphorylation, but ribosylation was not observed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871521     DOI: 10.1111/j.1348-0421.1996.tb03303.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  12 in total

1.  ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene.

Authors:  S Quan; T Imai; Y Mikami; K Yazawa; E R Dabbs; N Morisaki; S Iwasaki; Y Hashimoto; K Furihata
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance to rifampin by inactivating this antibiotic.

Authors:  S J Andersen; S Quan; B Gowan; E R Dabbs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

3.  Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes.

Authors:  Peter Spanogiannopoulos; Maulik Thaker; Kalinka Koteva; Nicholas Waglechner; Gerard D Wright
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

4.  Emergence of rifampin-resistant Rhodococcus equi in an infected foal.

Authors:  S Takai; K Takeda; Y Nakano; T Karasawa; J Furugoori; Y Sasaki; S Tsubaki; T Higuchi; T Anzai; R Wada; M Kamada
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic.

Authors:  S Quan; H Venter; E R Dabbs
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Characterization of In53, a class 1 plasmid- and composite transposon-located integron of Escherichia coli which carries an unusual array of gene cassettes.

Authors:  T Naas; Y Mikami; T Imai; L Poirel; P Nordmann
Journal:  J Bacteriol       Date:  2001-01       Impact factor: 3.490

7.  Integron-mediated rifampin resistance in Pseudomonas aeruginosa.

Authors:  C Tribuddharat; M Fennewald
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  Low-level resistance to rifampin in Streptococcus pneumoniae.

Authors:  Patricia Stutzmann Meier; Silvia Utz; Suzanne Aebi; Kathrin Mühlemann
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

9.  Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr.

Authors:  Jennifer Baysarowich; Kalinka Koteva; Donald W Hughes; Linda Ejim; Emma Griffiths; Kun Zhang; Murray Junop; Gerard D Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-18       Impact factor: 11.205

10.  A rifampin-hypersensitive mutant reveals differences between strains of Mycobacterium smegmatis and presence of a novel transposon, IS1623.

Authors:  David C Alexander; Joses R W Jones; Jun Liu
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.